Search

First Half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline

Growing late-stage research pipeline, addressing areas of high unmet medical need Pipeline includes areas such as rare skin disease, pulmonary fibrosis, oncology and central nervous system disease Net sales rise currency-adjusted by 9.5 percent to 11.

First half of 2021: Boehringer Ingelheim makes fundamental progress in research and development

Hypertension

Boehringer Ingelheim Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) complete negotiations for OFEV® (nintedanib) for PF-ILD

OFEV® is the first and only treatment available in Canada for progressive fibrosing interstitial lung diseases (PF-ILD), which affects patients across a wide variety of interstitial lung diseases (ILDs)

France

EMPA-KIDNEY trial showed significant benefit of JARDIANCE® (empagliflozin) in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people living with chronic kidney disease

EMPA-KIDNEY trial showed significant benefit of JARDIANCE® (empagliflozin) in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people living with chronic kidney disease

EMPA-KIDNEY, the largest and broadest dedicated SGLT2 inhibitor trial in chronic kidney disease, provides new evidence for patients commonly seen in clinical practice 1,2,3 Phase III trial also demonstrated a 14% statistically significant reduction

Scleroderma

Systemic sclerosis is a complex rare disease with a variable course. It presents with a range of symptoms involving several different organs

Diabetes

Aging seniors to reap long-term health benefits from Edmonton-based artificial intelligence project

First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas

Health Canada approves first treatment option for generalized pustular psoriasis flares in adults 

- Generalized pustular psoriasis differs significantly from plaque psoriasis in both its disease mechanism and severity.1 - In the EFFISAYIL®-1 trial, over half of the SPEVIGO® (spesolimab)-treated patients were free of pustules, one week after receiving

Human Health Partnering

Science Stories

Science and Innovation - Human Health Innovation - Science Stories

Alberta Boehringer Ingelheim collaboration fund announces new research for patients living with respiratory disease

AHEAD Program

The partnership program led by Boehringer Ingelheim Canada to address gaps in Canada’s health system for people living with T2D and heart failure. Click to read more.

COACH Program

The COACH Program addresses the unique needs of people living with heart failur and it's yielding promising results across Ontario. Find out more.

Equine asthma: Recognizing and managing respiratory issues in horses

Science Focus

Science and Innovation - Human Health Innovation - Science Focus

Vaccines

Science and Innovation - Animal Health Innovation - Vaccines

Global Careers Page

Join a global team of more than 52,000 passionate and talented individuals dedicated to improving the health of humans and animals worldwide.

The Research Process

Science and Innovation - Animal Health Innovation - Parasiticides

Lung Cancer

Livestock

Research Manitoba, Boehringer Ingelheim Canada and First Nations Health and Social Secretariat of Manitoba Announce Chronic Kidney Disease Screening Program in the Manitoba Adult First Nations Population

Boehringer Ingelheim increases commitments to sustainable development

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers

Search

First Half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline

First half of 2021: Boehringer Ingelheim makes fundamental progress in research and development

Hypertension

Boehringer Ingelheim Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) complete negotiations for OFEV® (nintedanib) for PF-ILD

France

EMPA-KIDNEY trial showed significant benefit of JARDIANCE® (empagliflozin) in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people living with chronic kidney disease

Scleroderma

Diabetes

Aging seniors to reap long-term health benefits from Edmonton-based artificial intelligence project

First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas

Health Canada approves first treatment option for generalized pustular psoriasis flares in adults

Human Health Partnering

Science Stories

Alberta Boehringer Ingelheim collaboration fund announces new research for patients living with respiratory disease

AHEAD Program

COACH Program

Equine asthma: Recognizing and managing respiratory issues in horses

Science Focus

Vaccines

Global Careers Page

The Research Process

Lung Cancer

Livestock

Research Manitoba, Boehringer Ingelheim Canada and First Nations Health and Social Secretariat of Manitoba Announce Chronic Kidney Disease Screening Program in the Manitoba Adult First Nations Population

Boehringer Ingelheim increases commitments to sustainable development

Boehringer Ingelheim Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) complete negotiations for OFEV® (nintedanib) for PF-ILD

EMPA-KIDNEY trial showed significant benefit of JARDIANCE® (empagliflozin) in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people living with chronic kidney disease

Health Canada approves first treatment option for generalized pustular psoriasis flares in adults 